Literature DB >> 15475449

Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis.

Maamoun M Al-Aynati1, Nikolina Radulovich, James Ho, Ming-Sound Tsao.   

Abstract

PURPOSE: Molecular analysis of pancreatic intraepithelial neoplasia lesions and ductal adenocarcinoma suggested a multistage paradigm for pancreatic duct cell carcinogenesis. This study investigated the molecular basis for the neoplastic duct cells in this pancreatic intraepithelial neoplasia-carcinoma sequence to acquire progressive enhancement of their proliferative potential. EXPERIMENTAL
DESIGN: Using tissue microarray blocks containing 15 to 40 pancreatic intraepithelial neoplasia lesions and ductal adenocarcinoma of pancreas, we studied by immunohistochemistry the expression profiles of cyclins and cyclin dependent kinases (CDKs) that regulate the G1-S cell cycle checkpoints. The role of cyclins D3 and D1 in three pancreatic cancer cell lines was investigated using specific short interfering RNA technique.
RESULTS: Cyclin D3 overexpression was noted the earliest in pancreatic intraepithelial neoplasia-1A and was prevalent in 90% to 100% of high-grade pancreatic intraepithelial neoplasias and ductal cancer. Cyclin A overexpression was also noted early and reached 50% to 100% of high-grade pancreatic intraepithelial neoplasias and cancer, but the percentage of abnormal duct cells showing overexpression of cyclin A was significantly lower than cyclin D3. Cyclin E overexpression occurred in 20% to 25% of high-grade pancreatic intraepithelial neoplasias and in 75% of ductal carcinoma. Cyclin D1 demonstrated the lowest frequency of overexpression that occurred late. CDK2 and CDK4 overexpression was also noted in early pancreatic intraepithelial neoplasias and progressively increased to reach 60% to 75% in carcinoma. The down-regulation of cyclin D3 mRNA and protein levels using specific short interfering RNA resulted in growth inhibition of pancreatic cancer cell lines.
CONCLUSION: The results provide additional insight into the mechanism of G1-S cell cycle checkpoints deregulation during stepwise pancreatic duct cell carcinogenesis, and suggest a p16-independent role for cyclin D3 in deregulating the G1 cell cycle checkpoints during early stages of pancreatic duct cell carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475449     DOI: 10.1158/1078-0432.CCR-04-0524

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.

Authors:  Sameh Mikhail; Christopher Albanese; Michael J Pishvaian
Journal:  Am J Pathol       Date:  2015-03-05       Impact factor: 4.307

2.  Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma.

Authors:  Mustafa Fuat Acikalin; Durmus Etiz; Melek Kezban Gurbuz; Erkan Ozudogru; Funda Canaz; Ertugrul Colak
Journal:  Med Oncol       Date:  2011-05-07       Impact factor: 3.064

3.  The sole presence of CDK4 is not a solid criterion for discriminating between tumor and healthy pancreatic tissues.

Authors:  Jordi Altirriba; Ainhoa García; Begoña Sánchez; Laura Haba; Sean Altekruse; Thomas Stratmann; Josep Antoni Bombí; Cristóbal Mezquita; Ramon Gomis; Conchi Mora
Journal:  Int J Cancer       Date:  2011-08-29       Impact factor: 7.396

4.  Cyclin-dependent kinase 4 overexpression is mostly independent of gene amplification and constitutes an independent prognosticator for nasopharyngeal carcinoma.

Authors:  Tzu-Ju Chen; Sung-Wei Lee; Li-Ching Lin; Ching-Yih Lin; Kwang-Yu Chang; Chien-Feng Li
Journal:  Tumour Biol       Date:  2014-04-27

5.  Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma.

Authors:  Nikolina Radulovich; Nhu-An Pham; Dan Strumpf; Lisa Leung; Wing Xie; Igor Jurisica; Ming-Sound Tsao
Journal:  Mol Cancer       Date:  2010-02-01       Impact factor: 27.401

6.  Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.

Authors:  Xiaobing Deng; Daina Z Ewton; Eileen Friedman
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth.

Authors:  Sarah K Johnson; Randy S Haun
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

8.  AKT1 mediates bypass of the G1/S checkpoint after genotoxic stress in normal human cells.

Authors:  Madhu A Lal; Dongsoon Bae; Tura C Camilli; Steven R Patierno; Susan Ceryak
Journal:  Cell Cycle       Date:  2009-05-25       Impact factor: 4.534

9.  Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.

Authors:  Teena Dhir; Christopher W Schultz; Aditi Jain; Samantha Z Brown; Alex Haber; Austin Goetz; Chunhua Xi; Gloria H Su; Liang Xu; James Posey; Wei Jiang; Charles J Yeo; Talia Golan; Michael J Pishvaian; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2019-08-05       Impact factor: 5.852

10.  Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D.

Authors:  Sandra Baumgart; Nai-Ming Chen; Jens T Siveke; Alexander König; Jin-San Zhang; Shiv K Singh; Elmar Wolf; Marek Bartkuhn; Irene Esposito; Elisabeth Heßmann; Johanna Reinecke; Julius Nikorowitsch; Marius Brunner; Garima Singh; Martin E Fernandez-Zapico; Thomas Smyrk; William R Bamlet; Martin Eilers; Albrecht Neesse; Thomas M Gress; Daniel D Billadeau; David Tuveson; Raul Urrutia; Volker Ellenrieder
Journal:  Cancer Discov       Date:  2014-04-02       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.